328 related articles for article (PubMed ID: 29313215)
21. Longitudinal assessment of the impact of higher body mass index on cancer-related fatigue in patients with breast cancer receiving chemotherapy.
Inglis JE; Janelsins MC; Culakova E; Mustian KM; Lin PJ; Kleckner IR; Peppone LJ
Support Care Cancer; 2020 Mar; 28(3):1411-1418. PubMed ID: 31267279
[TBL] [Abstract][Full Text] [Related]
22. Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer.
Yap NY; Tan NYT; Tan CJ; Loh KW; Ng RCH; Ho HK; Chan A
Breast Cancer Res Treat; 2020 Oct; 183(3):683-696. PubMed ID: 32696315
[TBL] [Abstract][Full Text] [Related]
23. Validation of inflammatory genetic variants associated with long-term cancer related fatigue in a large breast cancer cohort.
Kühl T; Behrens S; Jung AY; Obi N; Thöne K; Schmidt ME; Becher H; Chang-Claude J
Brain Behav Immun; 2018 Oct; 73():252-260. PubMed ID: 29763737
[TBL] [Abstract][Full Text] [Related]
24. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
[TBL] [Abstract][Full Text] [Related]
25. Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer.
Xia P; An HX; Dang CX; Radpour R; Kohler C; Fokas E; Engenhart-Cabillic R; Holzgreve W; Zhong XY
BMC Cancer; 2009 Dec; 9():454. PubMed ID: 20025731
[TBL] [Abstract][Full Text] [Related]
26. Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment.
Yap NY; Toh YL; Tan CJ; Acharya MM; Chan A
Cytokine; 2021 Aug; 144():155556. PubMed ID: 33985854
[TBL] [Abstract][Full Text] [Related]
27. Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.
Okanami Y; Ito Y; Watanabe C; Iijima K; Iwase T; Tokudome N; Takahashi S; Hatake K
Breast Cancer; 2011 Jul; 18(3):182-8. PubMed ID: 21394515
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Acupuncture Therapy for Chemotherapy-Related Cognitive Impairment in Breast Cancer Patients.
Tong T; Pei C; Chen J; Lv Q; Zhang F; Cheng Z
Med Sci Monit; 2018 May; 24():2919-2927. PubMed ID: 29735975
[TBL] [Abstract][Full Text] [Related]
29. Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy.
Williams AM; Shah R; Shayne M; Huston AJ; Krebs M; Murray N; Thompson BD; Doyle K; Korotkin J; van Wijngaarden E; Hyland S; Moynihan JA; Cory-Slechta DA; Janelsins MC
J Neuroimmunol; 2018 Jan; 314():17-23. PubMed ID: 29128118
[TBL] [Abstract][Full Text] [Related]
30. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients.
Zelek L; Cottu P; Tubiana-Hulin M; Vannetzel JM; Chollet P; Misset JL; Chouaki N; Marty M; Gamelin E; Culine S; Dieras V; Mackenzie S; Spielmann M
J Clin Oncol; 2002 May; 20(10):2551-8. PubMed ID: 12011135
[TBL] [Abstract][Full Text] [Related]
33. Re: Lymphopenia associated with adjuvant anthracycline/taxane regimens.
Cadoo K; Lowery M; McCaffrey J
Clin Breast Cancer; 2009 Nov; 9(4):262. PubMed ID: 19933084
[No Abstract] [Full Text] [Related]
34. A prospective study on the neurological complications of breast cancer and its treatment: Updated analysis three years after cancer diagnosis.
Fontes F; Pereira S; Castro-Lopes JM; Lunet N
Breast; 2016 Oct; 29():31-8. PubMed ID: 27394676
[TBL] [Abstract][Full Text] [Related]
35. Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study.
Cheung YT; Ng T; Shwe M; Ho HK; Foo KM; Cham MT; Lee JA; Fan G; Tan YP; Yong WS; Madhukumar P; Loo SK; Ang SF; Wong M; Chay WY; Ooi WS; Dent RA; Yap YS; Ng R; Chan A
Ann Oncol; 2015 Jul; 26(7):1446-51. PubMed ID: 25922060
[TBL] [Abstract][Full Text] [Related]
36. Predictors of baseline cancer-related cognitive impairment in cancer patients scheduled for a curative treatment.
Lycke M; Pottel L; Pottel H; Ketelaars L; Stellamans K; Van Eygen K; Vergauwe P; Werbrouck P; Goethals L; Schofield P; Boterberg T; Debruyne PR
Psychooncology; 2017 May; 26(5):632-639. PubMed ID: 27338029
[TBL] [Abstract][Full Text] [Related]
37. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
Hong JY; Park YH; Choi MK; Jung HA; Lee SJ; Ahn JS; Im YH
Clin Breast Cancer; 2015 Oct; 15(5):e287-92. PubMed ID: 25997855
[TBL] [Abstract][Full Text] [Related]
38. Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens.
Berger AM; Lockhart K; Agrawal S
Oncol Nurs Forum; 2009 Sep; 36(5):563-70. PubMed ID: 19726396
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Neurocognitive Function After Anthracycline-Based Chemotherapy vs Nonanthracycline-Based Chemotherapy.
Van Dyk K; Petersen L; Ganz PA
JAMA Oncol; 2016 Jul; 2(7):964-5. PubMed ID: 27100156
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
